Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRd vs Rd in High-Risk Smoldering Multiple Myeloma
NCT03673826Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Nov 2018
- Primary completion
- Aug 2024
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 4
01
Overview
A Phase 2 trial of carfilzomib in smoldering multiple myeloma (SMM), sponsored by HOVON. Started Nov 2018; status: active, not recruiting.
02
Drugs
carfilzomib
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT03673826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673826.